• 1
    Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 831.
  • 2
    Young HH: The early diagnosis and radical cure of carcinoma of the prostate: Being a study of 40 cases and presentation of a radical operation which was carried out in 4 cases. Bull Johns Hopkins Hosp 1905; 16: 315321.
  • 3
    Walsh PC, Donker PJ: Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 1982; 128: 492497.
  • 4
    Catalona WJ, Carvalhal GF, Mager DE, Smith DS: Potency, continence, and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999; 162: 433438.
  • 5
    Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994; 152: 18311836.
  • 6
    Eastham JA, Scardino, PT: Radical Prostatectomy, in WalshPC, RetikAB, VaughanEDJr, WeinAJ (eds): Campbell's Urology, ed 7. Philadelphia, WB Saunders Company, 1998, pp 25472564.
  • 7
    Gibbons RP, Correa RJ Jr, Brannen GE, et al: Total prostatectomy for localized prostatic cancer. J Urol 1984; 131: 7376.
  • 8
    Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994; 152: 18261830.
  • 9
    Carlin BI, Resnick MI: Anatomic approach to radical perineal prostatectomy. Urol Clin North Amer 1995; 22: 46173.
  • 10
    Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 115661.
  • 11
    Lu-Yao GL, Friedman M, Yao SL: Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol 1997; 157: 22192222.
  • 12
    Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491500.
  • 13
    Almroth A, Ljung G, Eklund T, et al: Value of sextant biopsies in the assessment of local cure following external beam radiotherapy of prostatic adenocarcinoma. Scand J Urol Nephrol 1998; 32: 111115.
  • 14
    Ragde H, Elgamal AA, Snow PB, et al: Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998; 83: 9891001.
  • 15
    D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969974.
  • 16
    Cohen JK, Miller R, Benoit R, et al: Five year outcomes of PSA and biopsy following cryosurgery as primary treatment for localized prostate cancer. J Urol 1998; 159: 252 (abstract 967).
  • 17
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975980.
  • 18
    Johansson JE, Holmberg L, Johansson S, et al: Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden. JAMA 1997; 277: 467471.
  • 19
    Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998; 160: 24282434.
  • 20
    Ventura SJ, Peters KD, Martin JA, Maurer JD: Births and deaths: United States, 1996. Mon Vital Stat Rep 1997; 46 (1 Suppl 2): 140.
  • 21
    Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368374.
  • 22
    Stein A, deKernion JB, Smith RB, et al: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992; 147: 942946.
  • 23
    Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 18501857.
  • 24
    Pound CR, Partin AW, Epstein JI, Walsh PC: Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Amer 1997; 24: 395406.
  • 25
    Smith DS, Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 17321736.
  • 26
    Oefelein MG, Smith ND, Grayhack JT, et al: Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol 1997; 158: 146065.
  • 27
    Krongrad A, Lai H, Lai S: Survival after radical prostatectomy. JAMA 1997; 278: 4446.
  • 28
    Roach M III, Lu J, Pilepich MV, et al: Long term survival in 1500 men treated for prostate cancer with radiotherapy alone: Radiation therapy oncology group (RTOG) protocols 7706, 7506, 8531, and 8610. J Urol 1998; 159: 219 (abstract 845).
  • 29
    Abbas F, Kattan MW, Wheeler TM, et al: Survival and cancer control for patients with cT1-T2 prostate cancer with intent to treat by radical prostatectomy. J Urol 1998; 159: 252 (abstract 964).
  • 30
    Fowler FJ Jr, Barry MJ, Lu-Yao G, et al: Patient-reported complications and follow-up treatment after radical prostatectomy: The National Medicare Experience: 1988–1990 (Updated June 1993). Urology 1993; 42: 622629.
  • 31
    Fowler FJ Jr, Barry MJ, Lu-Yao G, et al: Effect of radical prostatectomy for prostate cancer on patient quality of life: Results from a Medicare survey. Urology 1995; 45: 10071015.
  • 32
    Litwin MS, Hays RD, Fink A, et al: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129135.
  • 33
    Eastham JA, Kattan MW, Rogers E, et al: Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996; 156: 17071713.
  • 34
    Steiner MS, Morton RA, Walsh PC: Impact of anatomical radical prostatectomy on urinary continence. J Urol 1991; 145: 512515.
  • 35
    Geary ES, Dendinger TE, Freiha FS, Stamey TA: Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology 1995; 45: 10001006.
  • 36
    Weldon VE, Tavel FR, Neuwirth H: Continence, potency and morbidity after radical perineal prostatectomy. J Urol 1997; 158: 14701475.
  • 37
    Gaylis FD, Friedel WE, Armas OA: Radical retropubic prostatectomy outcomes at a community hospital. J Urol 1998; 159: 167171.
  • 38
    Talcott JA, Rieker P, Propert KJ, et al: Patient-reported impotence and incontinence after nervesparing radical prostatectomy. Natl Cancer Inst 1997; 89: 11171123.
  • 39
    Mettlin CJ, Murphy GP, Sylvester J, et al: Results of hospital cancer registry surveys by the American College of Surgeons: Outcomes of prostate cancer treatment by radical prostatectomy. Cancer 1997; 80: 18751881.
  • 40
    Montorsi F, Guazzoni G, Strambi LF, et al: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 1997; 158: 14081410.
  • 41
    Frazier HA, Robertson JE, Paulson DF: Radical prostatectomy: The pros and cons of the perineal versus retropubic approach. J Urol 1992; 147: 888890.
  • 42
    Litwiller SE, Reisch J, Roehrborn CG: Risk factors for impotence following radical prostatectomy: analysis in a community practice. J Urol 1998; 159: 219 (abstract 848).
  • 43
    Geary ES, Dendinger TE, Freiha FS, Stamey TA: Nerve sparing radical prostatectomy: A different view. J Urol 1995; 154: 145149.
  • 44
    Licht MR, Klein EA: Early hospital discharge after radical retropubic prostatectomy: Impact on cost and complication rate. Urology 1994; 44: 700704.
  • 45
    Lerner SE, Blute ML, Zincke H: Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995; 154: 11031109.
  • 46
    Abbas F, Kaplan M, Soloway MS: Induction androgen deprivation therapy before radical prostatectomy for prostate cancer: Initial results. Br J Urol 1996; 77: 423428.
  • 47
    Fair WR, Cookson MS, Stroumbakis N, et al: The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997; 49 (3A Suppl): 4655.
  • 48
    Cadeddu JA, Partin AW, Epstein JI, Walsh PC: Stage D1 (T1–3, N1–3, M0) prostate cancer: A case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 1997; 50: 251255.
  • 49
    Haymana JA, Wang S, McLaughlin PW, et al: 3-dimensional conformal radiation therapy following radical prostatectomy for prostate cancer. J Urol 1998; 159: 64 (abstract 238).
  • 50
    Newhall PM, Iselin CE, Aslan P, et al: Prognostic factors of PSA failure after radiation therapy following radical prostatectomy for prostate cancer. J Urol 1998; 64 (abstract 241).
  • 51
    McCarthy JF, Catalona WJ, Hudson MA: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J Urol 1994; 151: 15758.
  • 52
    D'Amico AV, Whittington R, Malkowicz SB, et al: Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial. J Clin Oncol. 1997; 15: 14651469
  • 53
    Rogers E, Ohori M, Kassabian VS, et al: Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels. J Urol 1995; 153: 104110.
  • 54
    Catalona WJ: Radical surgery for advanced prostate cancer and for radiation failures. J Urol 1992; 147: 916.
  • 55
    Byar DP, Corle DK: VACURG randomised trial of radical prostatectomy for stages I and II prostatic cancer: Veterans Administration Cooperative Urological Research Group. Urology 1981; 17 (4 Suppl): 711.
  • 56
    Paulson DF: Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. NCI Monogr 1988; 7: 127131.
  • 57
    Lu-Yao GL, Yao S-L: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906910.
  • 58
    Chodak GW: Prostate cancer. Lancet 1997; 349: 1551.
  • 59
    Ohori M, Goad JR, Wheeler TM, et al: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 18431849.
  • 60
    Partin AW, Lee BR, Carmichael M, et al: Radical prostatectomy for high grade disease: A reevaluation 1994. J Urol 1994; 151: 15831586.
  • 61
    Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1992; 270: 948954.